The emerging roles of microRNAs in cancer metabolism

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 301-308

  Chan, Brian ^a   Manley, Jacob ^a   Lee, Jae ^a   Singh, Shree Ram ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cancer therapy; Glycolysis; Metabolism; MicroRNAs; TCA cycle

Indexed keywords

GLUTAMINE; METFORMIN; MICRORNA; REACTIVE OXYGEN METABOLITE; AMINO ACID; GLUCOSE;

AMINO ACID METABOLISM; CANCER METABOLISM; CANCER THERAPY; CARCINOGENESIS; CITRIC ACID CYCLE; DRUG TARGETING; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; METASTASIS; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WARBURG EFFECT; BIOSYNTHESIS; CELL PROLIFERATION; CELL TRANSFORMATION; GENETICS; NEOPLASM; PATHOLOGY;

AMINO ACIDS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CITRIC ACID CYCLE; GLUCOSE; GLYCOLYSIS; HUMANS; LIPID METABOLISM; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84920059831     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.011     Document Type: Review

References (136)

1. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318(5858):1931-1934.
2. Flynt A.S., Lai E.C. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev. Genet. 2008, 9(11):831-842.
3. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
4. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic genelin-14 bylin-4 mediates temporal pattern formation inC. elegans. Cell 1993, 75:855-862.
5. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., Kim V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23(20):4051-4060.
6. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Rådmark O., Kim S., Kim V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425(6956):415-419.
7. Denli A.M., Tops B.B., Plasterk R.H., Ketting R.F., Hannon G.J. Processing of primary microRNAs by the Microprocessor complex. Nature 2004, 432(7014):231-235.
8. Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432(7014):235-240.
9. Landthaler M., Yalcin A., Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr. Biol. 2004, 14(23):2162-2167.
10. Carmell M.A., Hannon G.J. RNase III enzymes and the initiation of gene silencing. Nat. Struct. Mol. Biol. 2004, 11(3):214-218.
11. Zhang H., Kolb F.A., Jaskiewicz L., Westhof E., Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004, 118(1):57-68.
12. Han J., Lee Y., Yeom K.H., Nam J.W., Heo I., Rhee J.K., Sohn S.Y., Cho Y., Zhang B.T., Kim V.N. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006, 125(5):887-901.
13. Martin R., Smibert P., Yalcin A., Tyler D.M., Schäfer U., Tuschl T., Lai E.C. Drosophila pasha mutant distinguishes the canonical microRNA and mirtron pathways. Mol. Cell. Biol. 2009, 29(3):861-870.
14. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17(24):3011-3016.
15. Bohnsack M.T., Czaplinski K., Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10(2):185-191.
16. Hutvágner G., McLachlan J., Pasquinelli A.E., Bálint E., Tuschl T., Zamore P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001, 293(5531):834-838.
17. Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., Shiekhattar R. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436(7051):740-744.
18. Saito K., Ishizuka A., Siomi H., Siomi M.C. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells. PLoS Biol. 2005, 3(7):e235.
19. Okamura K., Ishizuka A., Siomi H., Siomi M.C. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 2004, 18(14):1655-1666.
20. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482(7385):347-355.
21. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat. Rev. Cancer 2012, 12(9):613-626.
22. Seol H.S., Akiyama Y., Shimada S., Lee H.J., Kim T.I., Chun S.M., Singh S.R., Jang S.J. Epigenetic silencing ofmicroRNA-373 to epithelial-mesenchymal transition in non-small cell lungcancerthrough IRAK2 and LAMP1 axes. Cancer Lett. 2014, 353(2):232-241.
23. Gao X., Jin W. The emerging role of tumor-suppressivemicroRNA-218 in targeting glioblastoma stemness. Cancer Lett. 2014, 353(1):25-31.
24. Su Y., Li X., Ji W., Sun B., Xu C., Li Z., Qian G., Su C. Small molecule with big role:MicroRNAsincancermetastatic microenvironments. Cancer Lett. 2014, 344(2):147-156.
25. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles formicroRNAsin the immune system. Nat. Rev. Immunol. 2010, 10(2):111-122.
26. Shen J., Stass S.A., Jiang F. MicroRNAsas potential biomarkers in human solid tumors. Cancer Lett. 2013, 329(2):125-136.
27. Dumortier O., Hinault C., Van Obberghen E. MicroRNAsand metabolism crosstalk in energy homeostasis. Cell Metab. 2013, 18(3):312-324.
28. Ross S.A., Davis C.D. The emerging role ofmicroRNAsand nutrition in modulating health and disease. Annu. Rev. Nutr. 2014, 34:305-336.
29. Chen S., Xue Y., Wu X., Le C., Bhutkar A., Bell E.L., Zhang F., Langer R., Sharp P.A. Global microRNA depletion suppresses tumor angiogenesis. Genes Dev. 2014, 28(10):1054-1067.
30. Singh S.R., Rameshwar P. MicroRNA in Development and in the Progression of Cancer 2014, Springer, New York.
31. Singh P.K., Brand R.E., Mehla K. MicroRNAsin pancreaticcancermetabolism. Nat. Rev. Gastroenterol. Hepatol. 2012, 9(6):334-344.
32. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
33. Singleterry J., Sreedhar A., Zhao Y. Components of cancer metabolism and therapeutic interventions. Mitochondrion 2014, 17:50-55.
34. Swietach P., Vaughan-Jones R.D., Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007, 26(2):299-310.
35. Nath K.A., Ngo E.O., Hebbel R.P., Croatt A.J., Zhou B., Nutter L.M. Alpha-Ketoacids scavenge H2O2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am. J. Physiol. 1995, 268. C227-36.
36. Calin G.A., Croce C.M. MicroRNAsignatures in human cancers. Nat. Rev. Cancer 2006, 6(11):857-866.
37. Kumar M.S., Lu J., Mercer K.L., et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
38. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11(2):85-95.
39. Chen B., Li H., Zeng X., Yang P., Liu X., Zhao X., Liang S. Roles ofmicroRNAoncancercellmetabolism. J. Transl. Med. 2012, 20(10):228.
40. Bienertova-Vasku J., Sana J., Slaby O. The role of microRNAs in mitochondria in cancer. Cancer Lett. 2013, 336(1):1-7.
41. Hatziapostolou M., Polytarchou C., Iliopoulos D. MiRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol. Metab. 2013, 24(7):361-373.
42. Reyes R.K., Motiwala T., Jacob S.T. Regulation of glucosemetabolismin hepatocarcinogenesis by microRNAs. Gene Expr. 2014, 16(2):85-92.
43. Tomasetti M., Nocchi L., Staffolani S., Manzella N., Amati M., Goodwin J., Kluckova K., Nguyen M., Strafella E., Bajzikova M., Peterka M., Lettlova S., Truksa J., Lee W., Dong L.F., Santarelli L., Neuzil J. MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. Antioxid. Redox Signal. 2014, (Apr 23). Epub ahead of print.
44. Wu M., Chan C. Prediction of therapeutic microRNA based on the human metabolic network. Bioinformatics 2014, (Jan 22). Epub ahead of print.
45. Bi H.C., Pan Y.Z., Qiu J.X., Krausz K.W., Li F., Johnson C.H., Jiang C.T., Gonzalez F.J., Yu A.M. N-methylnicotinamide and nicotinamide N-methyltransferase are associated withmicroRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 2014, 35(10):2264-2272.
46. Jin L.H., Wei C. Role of MicroRNAs in the Warburg Effect and Mitochondrial Metabolism in Cancer. Asian Pac. J. Cancer Prev. 2014, 15(17):7015-7019.
47. Tang H., Lee M., Sharpe O., Salamone L., Noonan E.J., Hoang C.D., Levine S., Robinson W.H., Shrager J.B. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems. FASEB J. 2012, 26(11):4710-4721.
48. Singh A., Happel C., Manna S.K., Acquaah-Mensah G., Carrerero J., Kumar S., Nasipuri P., Krausz K.W., Wakabayashi N., Dewi R., Boros L.G., Gonzalez F.J., Gabrielson E., Wong K.K., Girnun G., Biswal S. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013, 123(7):2921-2934.
49. Wei Z., Cui L., Mei Z., Liu M., Zhang D. MiR-181a mediates metabolic shift in colon cancer cells via thePTEN/AKT pathway. FEBS Lett. 2014, 588(9):1773-1779.
50. Park Y.Y., Kim S.B., Han H.D., Sohn B.H., Kim J.H., Liang J., Lu Y., Rodriguez-Aguayo C., Lopez-Berestein G., Mills G.B., Sood A.K., Lee J.S. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 2013, 58(1):182-191.
51. Dai D.W., Lu Q., Wang L.X., Zhao W.Y., Cao Y.Q., Li Y.N., Han G.S., Liu J.M., Yue Z.J. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 2013, 14(13):478.
52. Velez E., Yong X. MiR-17-3p regulates metabolism of prostate cancer cell. FASEB J. 2011, 25(903):7.
53. Ahmad A., Aboukameel A., Kong D., Wang Z., Sethi S., Chen W., Sarkar F.H., Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated bymiR-200in breast cancer cells. Cancer Res. 2011, 71(9):3400-3409.
54. Macheda M.L., Rogers S. Best JD Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202(3):654-662.
55. Fei X., Qi M., Wu B., Song Y., Wang Y., Li T. MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulatingGLUT3expression. FEBS Lett. 2012, 586(4):392-397.
56. Yang X., Cheng Y., Li P., Tao J., Deng X., Zhang X., Gu M., Lu Q., Yin C. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 2014, (Sep 30). Epub ahead of print.
57. Yamasaki T., Seki N., Yoshino H., Itesako T., Yamada Y., Tatarano S., Hidaka H., Yonezawa T., Nakagawa M., Enokida H. Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci. 2013 Nov, 104(11):1411-1419.
58. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase-2 bound tomitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 2009, 19(1):17-24.
59. Peschiaroli A., Giacobbe A., Formosa A., Markert E.K., Bongiorno-Borbone L., Levine A.J., Candi E., D'Alessandro A., Zolla L. Finazzi Agrò A, Melino G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013, 32(6):797-802.
60. Jiang S., Zhang L.F., Zhang H.W., Hu S., Lu M.H., Liang S., Li B., Li Y., Li D., Wang E.D. Liu MF.A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 2012, 31(8):1985-1998.
61. Fang R., Xiao T., Fang Z., Sun Y., Li F., Gao Y., Feng Y., Li L., Wang Y., Liu X., Chen H., Liu X.Y., Ji H. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J. Biol. Chem. 2012, 287(27):23227-23235.
62. Gregersen L.H., Jacobsen A., Frankel L.B., Wen J., Krogh A., Lund A.H. MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012, 12:232.
63. Zhao S., Liu H., Liu Y., Wu J., Wang C., Hou X., Chen X., Yang G., Zhao L., Che H., Bi Y., Wang H., Peng F., Ai J. MiR-143inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Lett. 2013, 333(2):253-260.
64. Jiang J.X., Gao S., Pan Y.Z., Yu C., Sun C.Y. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol. Med. Rep. 2014, 10(2):995-1002.
65. Tili E., Michaille J.J., Luo Z., Volinia S., Rassenti L.Z., Kipps T.J., Croce C.M. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 2012, 120(13):2631-2638.
66. Kim N.H., Cha Y.H., Kang S.E., Lee Y., Lee I., Cha S.Y., Ryu J.K., Na J.M., Park C., Yoon H.G., Park G.J., Yook J.I., Kim H.S. P53 regulates nuclear GSK-3 levels throughmiR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle 2013, 12(10):1578-1587.
67. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28(40):3526-3536.
68. Calin G.A., Cimmino A., Fabbri M., Ferracin M., Wojcik S.E., Shimizu M., Taccioli C., Zanesi N., Garzon R., Aqeilan R.I., Alder H., Volinia S., Rassenti L., Liu X., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15a andmiR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA 2008, 105(13):5166-5171.
69. Ichimi T., Enokida H., Okuno Y., Kunimoto R., Chiyomaru T., Kawamoto K., Kawahara K., Toki K., Kawakami K., Nishiyama K., Tsujimoto G., Nakagawa M., Seki N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer 2009, 125(2):345-352.
70. Muniyappa M.K., Dowling P., Henry M., Meleady P., Doolan P., Gammell P., Clynes M., Barron N. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur. J. Cancer 2009, 45(17):3104-3118.
71. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452(7184):230-233.
72. Sun Y., Zhao X., Zhou Y., Hu Y. MiR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol. Rep. 2012, 28(4):1346-1352.
73. Liu A.M., Xu Z., Shek F.H., Wong K.F., Lee N.P., Poon R.T., Chen J., Luk J.M. MiR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS ONE 2014, 9(1):e86872.
74. Wong T.S., Liu X.B., Chung-Wai Ho A., Po-Wing Yuen A., Wai-Man Ng R., Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123(2):251-257.
75. Kefas B., Comeau L., Erdle N., Montgomery E., Amos S., Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010, 12(11):1102-1112.
76. Li W., Wang J., Chen Q.D., Qian X., Li Q., Yin Y., Shi Z.M., Wang L., Lin J., Liu L.Z., Jiang B.H. Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway. PLoS ONE 2013, 8(6):e64924.
77. Li K.K., Pang J.C., Ching A.K., Wong C.K., Kong X., Wang Y., Zhou L., Chen Z., Ng H.K. MiR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum. Pathol. 2009, 40(9):1234-1243.
78. Kinoshita T., Nohata N., Yoshino H., Hanazawa T., Kikkawa N., Fujimura L., Chiyomaru T., Kawakami K., Enokida H., Nakagawa M., Okamoto Y., Seki N. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int. J. Oncol. 2012, 40(1):185-193.
79. Wilfred B.R., Wang W.X., Nelson P.T. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction thatmiR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 2007, 91(3):209-217.
80. Tanaka H., Sasayama T., Tanaka K., Nakamizo S., Nishihara M., Mizukawa K., Kohta M., Koyama J., Miyake S., Taniguchi M., Hosoda K., Kohmura E. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. J. Neurooncol. 2013, 111(3):273-283.
81. Favaro E., Ramachandran A., McCormick R., Gee H., Blancher C., Crosby M., Devlin C., Blick C., Buffa F., Li J.L., Vojnovic B., Pires das Neves R., Glazer P., Iborra F., Ivan M., Ragoussis J., Harris A.L. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010, 5(4):e10345.
82. Chen Z., Li Y., Zhang H., Huang P., Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29(30):4362-4368.
83. Puisségur M.P., Mazure N.M., Bertero T., Pradelli L., Grosso S., Robbe-Sermesant K., Maurin T., Lebrigand K., Cardinaud B., Hofman V., Fourre S., Magnone V., Ricci J.E., Pouysségur J., Gounon P., Hofman P., Barbry P., Mari B. MiR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011, 18(3):465-478.
84. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009, 10(4):273-284.
85. Eichner L.J., Perry M.C., Dufour C.R., Bertos N., Park M., St-Pierre J., Giguere V. MiR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab. 2010, 12(4):353-361.
86. Donadelli M., Dando I., Fiorini C., Palmieri M. Regulation ofmiR-23b expression and its dual role on ROS production and tumour development. Cancer Lett. 2014, 349(2):107-113.
87. Xu Y., Fang F., Zhang J., Josson S. St Clair WH, St Clair DK. miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS ONE 2010, 5(12):e14356.
88. Ebi H., Sato T., Sugito N., Hosono Y., Yatabe Y., Matsuyama Y., Yamaguchi T., Osada H., Suzuki M., Takahashi T. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009, 28(38):3371-3379.
89. Burchard J., Zhang C., Liu A.M., Poon R.T., Lee N.P., Wong K.F., Sham P.C., Lam B.Y., Ferguson M.D., Tokiwa G., Smith R., Leeson B., Beard R., Lamb J.R., Lim L., Mao M., Dai H., Luk J.M. MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol. Syst. Biol. 2010, 24(6):402.
90. Venkataraman S., Alimova I., Fan R., Harris P., Foreman N., Vibhakar R. MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS ONE 2010, 5(6):e10748.
91. Zhang X., Ng W.L., Wang P., Tian L., Werner E., Wang H., Doetsch P., Wang Y. MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα. Cancer Res. 2012, 72(18):4707-4713.
92. Mateescu B., Batista L., Cardon M., Gruosso T., de Feraudy Y., Mariani O., Nicolas A., Meyniel J.P., Cottu P., Sastre-Garau X., Mechta-Grigoriou F. MiR-141 andmiR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 2011, 17(12):1627-1635.
93. Li S.Z., Hu Y.Y., Zhao J., Zhao Y.B., Sun J.D., Yang Y.F., Ji C.C., Liu Z.B., Cao W.D., Qu Y., Liu W.P., Cheng G., Fei Z. MicroRNA-34a induces apoptosis in the humangliomacellline, A172, through enhanced ROS production andNOX2expression. Biochem. Biophys. Res. Commun. 2014, 444(1):6-12.
94. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression andglutaminemetabolism. Nature 2009, 458(7239):762-765.
95. Wang B., Hsu S.H., Frankel W., Ghoshal K., Jacob S.T. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012, 56(1):186-197.
96. Liu W., Le A., Hancock C., Lane A.N., Dang C.V., Fan T.W., Phang J.M. Reprogramming of proline andglutaminemetabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl. Acad. Sci. USA 2012, 109(23):8983-8988.
97. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA 2010, 107(16):7455-7460.
98. Wang P., Zhang L., Chen Z., Meng Z. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy 2013, 9(12):2171-2172.
99. Rotllan N., Fernández-Hernando C. MicroRNA regulation of cholesterol metabolism. Cholesterol 2012, 2012:847849.
100. Tili E., Michaille J.J., Luo Z., Volinia S., Rassenti L.Z., Kipps T.J., Croce C.M. The down-regulation ofmiR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 2012, 120(13):2631-2638.
101. Li X., Chen Y.T., Josson S., Mukhopadhyay N.K., Kim J., Freeman M.R., Huang W.C. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS ONE 2013, 8(8):e70987.
102. Cui M., Wang Y., Sun B., Xiao Z., Ye L., Zhang X. MiR-205modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem. Biophys. Res. Commun. 2014, 444(2):270-275.
103. Hsu S.H., Wang B., Kota J., Yu J., Costinean S., Kutay H., Yu L., Bai S., La Perle K., Chivukula R.R., Mao H., Wei M., Clark K.R., Mendell J.R., Caligiuri M.A., Jacob S.T., Mendell J.T., Ghoshal K. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions ofmiR-122in liver. J. Clin. Invest. 2012, 122(8):2871-2883.
104. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., Huang Y., Chen H.C., Lee C.H., Tsai T.F., Hsu M.T., Wu J.C., Huang H.D., Shiao M.S., Hsiao M., Tsou A.P. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 2012, 122(8):2884-2897.
105. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., Chrétien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., Munnich A., Rötig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39(6):776-780.
106. Zhang D.G., Zheng J.N., Pei D.S. P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. Mol. Cancer 2014, 13:115.
107. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., Mo Y.Y. P53represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 2009, 106(9):3207-3212.
108. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., Dalla-Favera R., Dang C.V. C-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 1997, 94(13):6658-6663.
109. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. C-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043):839-843.
110. Godlewski J., Nowicki M.O., Bronisz A., Nuovo G., Palatini J., De Lay M., Van Brocklyn J., Ostrowski M.C., Chiocca E.A., Lawler S.E. MicroRNA-451 regulates LKB1/AMPKsignaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37(5):620-632.
111. Iliopoulos D., Polytarchou C., Hatziapostolou M., Kottakis F., Maroulakou I.G., Struhl K., Tsichlis P.N. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal 2009, 2(92):ra62.
112. Nagaraja A.K., Creighton C.J., Yu Z., Zhu H., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M. A link betweenmir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24(2):447-463.
113. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70(12):5184-5193.
114. Bao L., Yan Y., Xu C., Ji W., Shen S., Xu G., Zeng Y., Sun B., Qian H., Chen L., Wu M., Su C., Chen J. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett. 2013, 337(2):226-236.
115. Zeng W., Liu P., Pan W., Singh S.R., Wei Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2014, (Feb 4). pii:S0304-3835(14)00089-5.
116. Gaglio D., Metallo C.M., Gameiro P.A., Hiller K., Danna L.S., Balestrieri C., Alberghina L., Stephanopoulos G., Chiaradonna F. Oncogenic K-Ras decouples glucose andglutaminemetabolism to support cancer cell growth. Mol. Syst. Biol. 2011, 7:523.
117. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., Yan H., Wang W., Chen S., Viale A., Zheng H., Paik J.H., Lim C., Guimaraes A.R., Martin E.S., Chang J., Hezel A.F., Perry S.R., Hu J., Gan B., Xiao Y., Asara J.M., Weissleder R., Wang Y.A., Chin L., Cantley L.C., DePinho R.A. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149(3):656-670.
118. Yu S., Lu Z., Liu C., Meng Y., Ma Y., Zhao W., Liu J., Yu J., Chen J. MiRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70(14):6015-6025.
119. Liao W.T., Ye Y.P., Zhang N.J., Li T.T., Wang S.Y., Cui Y.M., Qi L., Wu P., Jiao H.L., Xie Y.J., Zhang C., Wang J.X., Ding Y.Q. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targetingKRAS, PIK3CD and BCL2. J. Pathol. 2014, 232(4):415-427.
120. Soon P., Kiaris H. MicroRNAs in the tumour microenvironment: big role for small players. Endocr. Relat. Cancer 2013, 20(5). R257-67.
121. Chou J., Shahi P., Werb Z. MicroRNA-mediated regulation of the tumormicroenvironment. Cell Cycle 2013, 12(20):3262-3271.
122. Fiaschi T., Chiarugi P. Oxidative stress,tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int. J. Cell Biol. 2012, 2012:762825.
123. Lunt S.J., Chaudary N., Hill R.P. The tumormicroenvironmentand metastatic disease. Clin. Exp. Metastasis 2009, 26(1):19-34.
124. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
125. Taddei M.L., Giannoni E., Comito G., Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013, 341(1):80-96.
126. Sun P., Hu J.W., Xiong W.J., Mi J. MiR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts. Asian Pac. J. Cancer Prev. 2014, 15(10):4245-4250.
127. Tomasetti M., Neuzil J., Dong L. MicroRNAs as regulators of mitochondrial function: role in cancer suppression. Biochim. Biophys. Acta 2014, 1840(4):1441-1453.
128. Sotgia F., Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., Howell A., Philp N.J., Pestell R.G., Lisanti M.P. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle 2012, 11(7):1445-1454.
129. Phan L.M., Yeung S.C., Lee M.H. Cancermetabolicreprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 2014, 11(1):1-19.
130. Drakaki A., Hatziapostolou M., Iliopoulos D. Therapeutically targeting microRNAs in liver cancer. Curr. Pharm. Des. 2013, 19(7):1180-1191.
131. Pulito C., Donzelli S., Muti P., Puzzo L., Strano S., Blandino G. MicroRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann. Transl. Med. 2014, 2(6):58.
132. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol. Med. 2012, 4(3):143-159.
133. Park J.K., Kogure T., Nuovo G.J., Jiang J., He L., Kim J.H., Phelps M.A., Papenfuss T.L., Croce C.M., Patel T., Schmittgen T.D. MiR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011, 71(24):7608-7616.
134. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. TherapeuticmicroRNAdelivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6):1005-1017.
135. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., Weidhaas J.B., Bader A.G., Slack F.J. Systemic delivery of tumor suppressormicroRNAmimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19(6):1116-1122.
136. Takeshita F., Patrawala L., Osaki M., Takahashi R.U., Yamamoto Y., Kosaka N., Kawamata M., Kelnar K., Bader A.G., Brown D., Ochiya T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18(1):181-187.